Abstract: Provided herein are methods of treating multiple myeloma and methods of inhibiting amyloid formation in a subject. The methods provided herein include the administration of an antibody that binds to misfolded light chains in combination with an anti-CD38 antibody. The anti-CD38 is for example Daratumumab, Isatuximab, CID-103 (CASI Pharma), or Moro3087 (Morphosys) or a combination thereof.

Abstract: Provided herein are methods of treating amyloidosis disease and disorder in a subject, and methods of decreasing the amount of amyloid deposits in an organ. The methods provided herein include the administration of an antibody, alone or in combination with another therapy. In one aspect, the disclosure provides a method of treating an amyloidosis disease or disorder in a subject including administering to the subject the pharmaceutical composition of the invention and an additional therapy, thereby treating the amyloidosis disease or disorder in the subject.

Abstract: The invention is directed to a pediatric oral suspension composition containing amoxicillin and clavulanate potassium where the clavulanate potassium is present in an amount equal to or less than about 21.5 mg/5 mL, and a method of treating bacterial infections by providing between about one to about fourteen dosage days of the composition. Also disclosed are methods of treating a patient comprising administering amoxicillin and clavulanate potassium to the patient in dosages of at least about 80 mg/kg/day of the amoxicillin and from about 1.66 mg/kg/day to about 2.84 mg/kg/day of the clavulanate potassium. The methods are useful for treating pediatric otitis media, treating a drug resistant bacterial infection, or treating beta-lactamase producing Haemophilus influenzae or Moraxella catarrhalis in a patient under 24 months of age.

Abstract: The invention is directed to a pediatric oral suspension composition containing amoxicillin and clavulanate potassium where the clavulanate potassium is present in an amount equal to or less than about 21.5 mg/5 mL, and a method of treating bacterial infections by providing between about one to about fourteen dosage days of the composition.

Abstract: The invention is directed to a pediatric oral suspension composition containing amoxicillin and clavulanate potassium where the clavulanate potassium is present in an amount equal to or less than about 21.5 mg/5 mL, and a method of treating bacterial infections by providing between about one to about fourteen dosage days of the composition.

Abstract: A MUX, DEMUX or integrated combination MUX/DEMUX utilizing a discrete dispersion device (herein referred to as “D3” device), which includes at least one input port, at least one output port and an optical planar waveguide comprising a synergetic photonic bandgap quasi-crystal (“PBQC”) for guiding and supporting optical signals in a work bandwidth. The D3 device achieves a flat-top response for each channel, high channel isolation and background noise suppression.

Abstract: The present invention provides a photonic multi-bandgap structure, herein also referred to as photonic bandgap quasi-crystal (“PBQC”), that can direct light, having wavelength components within a selected passband (&Dgr;&lgr;), from an input port, to a predefined output port, while providing an integrating element for Planar Lightwave Circuits. A photonic bandgap quasi-crystal of the invention combines in a planar waveguide spectrally selective properties of gratings, focusing properties of elliptical mirrors, superposition properties of thick holograms, photonic bandgaps of periodic structures, and flexibility of binary lithography. A photonic structure of the invention can be utilized, for example, as an integrating spectrally sensitive element in a variety of optical devices that can include, but are not limited to, optical switches, optical multiplexer/demultiplexers, multi-wavelength lasers, and channel monitors in Wavelength Division Mulitplexing (WDM) telecommunications system.

Abstract: The present invention provides a photonic multi-bandgap structure, herein also referred to as photonic bandgap quasi-crystal (“PBQC”), that can direct light, having wavelength components within a selected passband (&Dgr;&lgr;), from an input port, to a predefined output port, while providing an integrating element for Planar Lightwave Circuts. A photonic bandgap quasi-crystal of the invention combines in a planar waveguide spectrally selective properties of gratings, focusing properties of elliptical mirrors, superposition properties of thick holograms, photonic bandgaps of periodic structures, and flexibility of binary lithography. A photonic structure of the invention can be utilized, for example, as an integrating spectrally sensitive element in a variety of optical devices that can include, but are not limited to, optical switches, optical multiplexer/demultiplexers, multi-wavelength lasers, and channel monitors in Wavelength Division Multiplexing (WDM) telecommunications system.